2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Antonio Palumbo, MD, presenting abstract LBA4, Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study during Plenary Session including Science of Oncology Award and Lecture

Antonio Palumbo, MD, presenting abstract LBA4, Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study during Plenary Session including Science of Oncology Award and Lecture

Chicago, IL - 2016 ASCO Annual Meeting - Antonio Palumbo, MD, presenting abstract LBA4, Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study during Plenary Session including Science of Oncology Award and Lecture at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Phil McCarten 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org